Novel misfolded proteins in ADRD: proteomics, genetics, and clinical-pathological correlations

ADRD 中的新型错误折叠蛋白:蛋白质组学、遗传学和临床病理相关性

基本信息

  • 批准号:
    9905466
  • 负责人:
  • 金额:
    $ 19.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-15 至 2022-01-31
  • 项目状态:
    已结题

项目摘要

The heterogeneous pathologies of Alzheimer's disease and related dementias (ADRD) are still incompletely understood. There is no perfect animal model to study these diseases. Four known aberrantly misfolded proteins are commonly detected via neuropathologic examination of brains with ADRD: Aβ, Tau, TDP-43, and/or α-Synuclein. Our preliminary data indicate that there are more pathogenic protein species awaiting identification. Characterization of these proteins may be relevant to the development of both diagnostic and therapeutic strategies for ADRD. The goals of this research project are to identify previously uncharacterized, misfolded, and aberrantly processed proteins in ADRD; to resolve gene variants that modulate the severity and heterogeneity of dementia through the novel misfolded proteins; and, to perform clinical-pathological correlation, focusing on these novel proteins, to identify new disease-associated pathologic biomarkers. We will leverage the resources of the University of Kentucky AD Center (UK-ADC) biobank and the University of Kentucky Proteomics Core Facility, to execute the following Specific Aims: Specific Aim 1. Analyse detergent-insoluble protein extracts from human amygdala (snap-frozen at autopsy) to investigate whether as yet uncharacterized misfolded proteins are detectable in ADRD. Polypeptides from the detergent-insoluble, urea-soluble protein fractions of amygdala will be interrogated using mass spectrometry. We have on-hand amygdalae from 40 UK-ADC subjects which incorporate a spectrum of clinical and pathologic features. Immunohistochemistry and biochemical studies will be performed to determine the best candidate proteins for additional studies (Aims 2 and 3). Specific Aim 2. Construct a robust and harmonized database with exonic sequencing to localize genetic regions associated with novel misfolded proteins in ADRD. We will test the association between dementia and rare, exonic (`mis-sense') genetic variants in genes that encode candidate misfolded proteins (Aim 1). Genetics data augmented with rich neuropathologic endophenotypes and longitudinal clinical data will enable insights into novel mechanisms that drive dementia. Large-scale datasets (NACC, ADGC, ADSP) will be aggregated and harmonized to test the genetic drivers of clinical and neuropathology-based endophenotypes focusing on novel candidate genes. Candidate target genes have already been identified. Specific Aim 3. Establish the clinical-pathologic correlation for the novel misfolded proteinopathies in ADRD. We will test the association between the potential novel proteinopathies (from Aim 1) with cognitive impairment, factoring in known markers Aβ, tau, α-Synuclein, and TDP-43, as well as cerebrovascular pathologies. We have 370 samples available for analyses (both sexes) from the UK-ADC, which should be statistically powered to test our hypothesis that the presence and severity of novel misfolding protein pathologies are associated with cognitive impairment.
阿尔茨海默病和相关痴呆(ADRD)的异质性病理仍然存在

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER T. NELSON其他文献

PETER T. NELSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER T. NELSON', 18)}}的其他基金

Core D: University of Kentucky Alzheimer's Disease Core Center
核心 D:肯塔基大学阿尔茨海默病核心中心
  • 批准号:
    10662352
  • 财政年份:
    2021
  • 资助金额:
    $ 19.13万
  • 项目类别:
Core D: University of Kentucky Alzheimer's Disease Core Center
核心 D:肯塔基大学阿尔茨海默病核心中心
  • 批准号:
    10459469
  • 财政年份:
    2021
  • 资助金额:
    $ 19.13万
  • 项目类别:
Core D: University of Kentucky Alzheimer's Disease Core Center
核心 D:肯塔基大学阿尔茨海默病核心中心
  • 批准号:
    10261965
  • 财政年份:
    2021
  • 资助金额:
    $ 19.13万
  • 项目类别:
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic
海马硬化的新发病机制,一种常见的阿尔茨海默病模拟
  • 批准号:
    9912063
  • 财政年份:
    2017
  • 资助金额:
    $ 19.13万
  • 项目类别:
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic
海马硬化的新发病机制,一种常见的阿尔茨海默病模拟
  • 批准号:
    9402752
  • 财政年份:
    2017
  • 资助金额:
    $ 19.13万
  • 项目类别:
Testing a therapeutic strategy for hippocampal sclerosis of aging, a key AD mimic
测试老年海马硬化的治疗策略,这是一种关键的 AD 模拟
  • 批准号:
    9055456
  • 财政年份:
    2016
  • 资助金额:
    $ 19.13万
  • 项目类别:
Sexually dimorphic miR-497 regulates alpha-synuclein and alpha-synucleinopathy
性二态性 miR-497 调节 α-突触核蛋白和 α-突触核蛋白病
  • 批准号:
    8638195
  • 财政年份:
    2013
  • 资助金额:
    $ 19.13万
  • 项目类别:
CELLULAR CHANGES ALTERING SYNAPTIC CONNECTIVITY IN PRECLINICAL AD
临床前 AD 中细胞变化改变突触连接
  • 批准号:
    9282762
  • 财政年份:
    2013
  • 资助金额:
    $ 19.13万
  • 项目类别:
CELLULAR CHANGES ALTERING SYNAPTIC CONNECTIVITY IN PRECLINICAL AD
临床前 AD 中细胞变化改变突触连接
  • 批准号:
    9084441
  • 财政年份:
    2013
  • 资助金额:
    $ 19.13万
  • 项目类别:
Sexually dimorphic miR-497 regulates alpha-synuclein and alpha-synucleinopathy
性二态性 miR-497 调节 α-突触核蛋白和 α-突触核蛋白病
  • 批准号:
    8739560
  • 财政年份:
    2013
  • 资助金额:
    $ 19.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了